Skip to main content
Erschienen in:

16.01.2019 | review

Current lymphoma diagnostic standards: the pathologists’ view

verfasst von: Magdalena M. Gerlach, Prof. Dr. Alexandar Tzankov

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Summary

This short review aims at summarizing the current standards of lymphoma diagnostics and some novelties in the recent WHO classification. The importance of close collaboration between clinicians and pathologists to render the correct diagnosis and to find the most appropriate treatment for each individual patient is highlighted. In lymphomas, the diagnostic evaluation of histopathology, immune phenotype and genetics are puzzle pieces that have to be put into a broader context with the help of the information given by the clinical colleagues, such as patient’s age and sex, location of the lesion, previous medical history and medication. An excision of the affected lymph node is always preferable to fine needle biopsies, as—in many instances—only the evaluation of the whole specimen allows for reliable diagnosis, grading and additional investigations.
The new WHO classification entailed many changes in the category of diffuse large B‑cell lymphoma and high-grade B‑cell lymphoma. The obligatory specification of the cell of origin in diffuse large B‑cell lymphoma is obtained via additional immunohistochemical stainings. The identification of high-grade B‑cell lymphomas with genetic double/triple hits, requiring a more aggressive management, can only be achieved by the detection of chromosomal translocations (MYC, BCL2 and/or BCL6). Significant changes in the classification of T‑cell lymphomas have occurred due to the recognition of the follicular T‑helper cell origin in some instances, and sharpening diagnostic borders of intestinal T‑cell- and Epstein-Barr-virus-associated proliferations. Finally, the discovery of disease-defining and/or prognostically relevant mutations makes the introduction of proper routine molecular testing mandatory.
Literatur
2.
Zurück zum Zitat Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014;11(4):4449–527.CrossRef Schinasi L, Leon ME. Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis. Int J Environ Res Public Health. 2014;11(4):4449–527.CrossRef
3.
Zurück zum Zitat Tzankov A, Dirnhofer S. A pattern-based approach to reactive lymphadenopathies. Semin Diagn Pathol. 2018;35(1):4–19.CrossRef Tzankov A, Dirnhofer S. A pattern-based approach to reactive lymphadenopathies. Semin Diagn Pathol. 2018;35(1):4–19.CrossRef
4.
Zurück zum Zitat Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc. 2012;87(6):571–80.CrossRef Ansell SM, Armitage JO. Positron emission tomographic scans in lymphoma: convention and controversy. Mayo Clin Proc. 2012;87(6):571–80.CrossRef
5.
Zurück zum Zitat Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2017.
6.
Zurück zum Zitat Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. Ann Hematol. 2013;92(11):1537–41.CrossRef Attarbaschi A, Beishuizen A, Mann G, Rosolen A, Mori T, Uyttebroeck A, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. Ann Hematol. 2013;92(11):1537–41.CrossRef
7.
Zurück zum Zitat Louissaint A Jr., Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–100.CrossRef Louissaint A Jr., Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016;128(8):1093–100.CrossRef
8.
Zurück zum Zitat Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–47.CrossRef Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B‑cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–47.CrossRef
9.
Zurück zum Zitat Copie-Bergman C, Niedobitek G, Mangham DC, Selves J, Baloch K, Diss TC, et al. Epstein-Barr virus in B‑cell lymphomas associated with chronic suppurative inflammation. J Pathol. 1997;183(3):287–92.CrossRef Copie-Bergman C, Niedobitek G, Mangham DC, Selves J, Baloch K, Diss TC, et al. Epstein-Barr virus in B‑cell lymphomas associated with chronic suppurative inflammation. J Pathol. 1997;183(3):287–92.CrossRef
10.
Zurück zum Zitat Cheuk W, Chan AC, Chan JK, Lau GT, Chan VN, Yiu HH. Metallic implant-associated lymphoma: a distinct subgroup of large B‑cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol. 2005;29(6):832–6.CrossRef Cheuk W, Chan AC, Chan JK, Lau GT, Chan VN, Yiu HH. Metallic implant-associated lymphoma: a distinct subgroup of large B‑cell lymphoma related to pyothorax-associated lymphoma? Am J Surg Pathol. 2005;29(6):832–6.CrossRef
11.
Zurück zum Zitat Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–20.CrossRef Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–20.CrossRef
12.
Zurück zum Zitat Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, et al. Hodgkin lymphoma in Tyrol—a population-based study. Ann Hematol. 2009;88(5):449–56.CrossRef Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, et al. Hodgkin lymphoma in Tyrol—a population-based study. Ann Hematol. 2009;88(5):449–56.CrossRef
13.
Zurück zum Zitat Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, et al. Mutational landscape of B‑cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178(1):48–56.CrossRef Menter T, Juskevicius D, Alikian M, Steiger J, Dirnhofer S, Tzankov A, et al. Mutational landscape of B‑cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178(1):48–56.CrossRef
15.
Zurück zum Zitat Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B‑cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRef Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B‑cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRef
16.
Zurück zum Zitat Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–43.CrossRef Gutiérrez-García G, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, Mate JL, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy. Blood. 2011;117(18):4836–43.CrossRef
17.
Zurück zum Zitat Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B‑cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–7.CrossRef Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B‑cell lymphoma treated with rituximab. J Clin Oncol. 2011;29(2):200–7.CrossRef
18.
Zurück zum Zitat Lunning MA, Vose JM. Angioimmunoblastic T‑cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095–102.CrossRef Lunning MA, Vose JM. Angioimmunoblastic T‑cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095–102.CrossRef
19.
Zurück zum Zitat Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods Mol Biol. 2013;999:223–30.CrossRef Weiss LM, Chen YY. EBER in situ hybridization for Epstein-Barr virus. Methods Mol Biol. 2013;999:223–30.CrossRef
20.
Zurück zum Zitat Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14.CrossRef Howlett C, Snedecor SJ, Landsburg DJ, Svoboda J, Chong EA, Schuster SJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015;170(4):504–14.CrossRef
21.
Zurück zum Zitat Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B‑cell lymphomas. Blood. 2011;117(8):2319–31.CrossRef Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, et al. Double-hit B‑cell lymphomas. Blood. 2011;117(8):2319–31.CrossRef
22.
Zurück zum Zitat Hoeller S, Tzankov A, Stenner F, Dirnhofer S. When and how to test for C‑MYC in aggressive B cell lymphomas. J Hematop. 2015;8(1):13–20.CrossRef Hoeller S, Tzankov A, Stenner F, Dirnhofer S. When and how to test for C‑MYC in aggressive B cell lymphomas. J Hematop. 2015;8(1):13–20.CrossRef
23.
Zurück zum Zitat Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B‑cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958–71.CrossRef Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B‑cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014;27(7):958–71.CrossRef
24.
Zurück zum Zitat Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259–75.CrossRef Swerdlow SH, Kuzu I, Dogan A, Dirnhofer S, Chan JK, Sander B, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259–75.CrossRef
25.
Zurück zum Zitat Wang YL. MYD88 mutations and sensitivity to Ibrutinib therapy. J Mol Diagn. 2018;20(2):264–6.CrossRef Wang YL. MYD88 mutations and sensitivity to Ibrutinib therapy. J Mol Diagn. 2018;20(2):264–6.CrossRef
26.
Zurück zum Zitat Turakhia S, Lanigan C, Hamadeh F, Swerdlow SH, Tubbs RR, Cook JR. Immunohistochemistry for BRAF V600E in the differential diagnosis of hairy cell leukemia vs other splenic B‑cell lymphomas. Am J Clin Pathol. 2015;144(1):87–93.CrossRef Turakhia S, Lanigan C, Hamadeh F, Swerdlow SH, Tubbs RR, Cook JR. Immunohistochemistry for BRAF V600E in the differential diagnosis of hairy cell leukemia vs other splenic B‑cell lymphomas. Am J Clin Pathol. 2015;144(1):87–93.CrossRef
27.
Zurück zum Zitat Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125(8):1207–16.CrossRef Pettirossi V, Santi A, Imperi E, Russo G, Pucciarini A, Bigerna B, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125(8):1207–16.CrossRef
28.
Zurück zum Zitat Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B‑cell leukemias. Blood. 1995;85(6):1580–9.PubMed Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B‑cell leukemias. Blood. 1995;85(6):1580–9.PubMed
29.
Zurück zum Zitat Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol. 2018;97(12):2269–78.CrossRef Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. Ann Hematol. 2018;97(12):2269–78.CrossRef
30.
Zurück zum Zitat Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122–30.CrossRef Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016;127(17):2122–30.CrossRef
31.
Zurück zum Zitat Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016;128(26):3101–12.PubMedPubMedCentral Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016;128(26):3101–12.PubMedPubMedCentral
32.
Zurück zum Zitat Obermann EC, Mueller N, Rufle A, Menter T, Mueller-Garamvoelgyi E, Cathomas G, et al. Clonal relationship of classical Hodgkin lymphoma and its recurrences. Clin Cancer Res. 2011;17(16):5268–74.CrossRef Obermann EC, Mueller N, Rufle A, Menter T, Mueller-Garamvoelgyi E, Cathomas G, et al. Clonal relationship of classical Hodgkin lymphoma and its recurrences. Clin Cancer Res. 2011;17(16):5268–74.CrossRef
33.
Zurück zum Zitat Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, et al. Distinct genetic evolution patterns of relapsing diffuse large B‑cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385–95.CrossRef Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, et al. Distinct genetic evolution patterns of relapsing diffuse large B‑cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30(12):2385–95.CrossRef
34.
Zurück zum Zitat Montoto S. Treatment of patients with transformed lymphoma. Hematology Am Soc Hematol Educ Program. 2015;2015:625–30.CrossRef Montoto S. Treatment of patients with transformed lymphoma. Hematology Am Soc Hematol Educ Program. 2015;2015:625–30.CrossRef
Metadaten
Titel
Current lymphoma diagnostic standards: the pathologists’ view
verfasst von
Magdalena M. Gerlach
Prof. Dr. Alexandar Tzankov
Publikationsdatum
16.01.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0472-y